This article is part of a series on The Scientific Basis of Rheumatology: A Decade of Progress, edited by Peter Lipsky and Ravinder Maini.ReviewDevelopments in the scientific and clinical understanding of inflammatory myopathiesRheumatology Unit, Department of Medicine, Karolinska University Hospital – Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden
Arthritis Research & Therapy 2008, 10:220doi:10.1186/ar2501
AbstractThe idiopathic inflammatory myopathies are chronic autoimmune disorders sharing the clinical symptom of muscle weakness and, in typical cases, inflammatory cell infiltrates in muscle tissue. During the last decade, novel information has accumulated supporting a role of both the innate and adaptive immune systems in myositis and suggesting that different molecular pathways predominate in different subsets of myositis. The type I interferon activity is one such novel pathway identified in some subsets of myositis. Furthermore, nonimmunological pathways have been identified, suggesting that factors other than direct T cell-mediated muscle fibre necrosis could have a role in the development of muscle weakness. |




on Google Scholar








author email
corresponding author email